Excision BioTherapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
134 Coolidge Ave, Watertown, Massachuset...Website
excision.bioRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About Excision BioTherapeutics
Excision BioTherapeutics, Inc., is a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases. Excision is focused on improving the lives of chronically ill patients by excising viral genomes from infected individuals. By using CRISPR in unique ways, the Company has already demonstrated the first functional cure for HIV in animals. Excision is developing technologies and IP developed at Temple University and U.C. Berkeley. Excision is located in San Francisco, California and is supported by ARTIS Ventures, GreatPoint Ventures, Norwest Venture Partners, Adjuvant Capital, Cota Capital, WRVI Capital, IndusAge Partners, Loreda Holdings, Olive Tree, Anzu Partners, SilverRidge Venture Partners, Oakhouse Ventures, and Gaingels.Explore more
Excision BioTherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Excision BioTherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Excision BioTherapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Excision BioTherapeutics
Excision BioTherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Excision BioTherapeutics is spiking on competitors!
Check if Excision BioTherapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Excision BioTherapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Excision BioTherapeutics has new funding data
Product Launch: Get notified when Excision BioTherapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined Excision BioTherapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Excision BioTherapeutics
Compare insights from companies similar to Excision BioTherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Excision BioTherapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Excision BioTherapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Excision BioTherapeutics.
Excision BioTherapeutics financials insights
Gather financial insights about Excision BioTherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Angel/Seed
$10M
2021
Other Financing Round
$60M
Excision BioTherapeutics Tech Stack
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Move
Board of Directors
Lateral Move
Executive Move
Excision BioTherapeutics News & Media
Excision BioTherapeutics Announces Publication Highlighting EBT-107 for the Treatment of Chronic Hepatitis B in bioRxiv
Preclinical data supports advancing EBT-107 into IND-enabling studies and clinical trialsExcision BioTherapeutics Presents Data from HBV and HSV Programs at the ASGCT 2025 Annual Meeting
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision” or the “Company”), a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced new data presentations from its preclinical programs, hepatitis B virus (HBV), EBT-107 and herpes simplex virus (HSV-1) keratitis, EBT-104 at the 2025 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 13–17 in New Orleans, Louisiana.Excision BioTherapeutics Announces Oral Presentation at the 5th Genome Editing Therapeutics Summit
SAN FRANCISCO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a biotechnology company developing CRISPR-based therapies to cure serious viral infectious diseases, today announced that Dr. Ryo Takeuchi, Senior Director, Genome Editing, will deliver an oral presentation at the 5th Genome Editing Therapeutics Summit (formerly CRISPR 2.0), which is taking place from December 3-5, 2024, in Boston, MA. Dr. Takeuchi will also be chairing a session at the cPresentation at the 2024 International HBV Meeting Highlights Antiviral Activity of EBT-107 as a Potential Anti-HBV Therapy
SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure deadly and debilitating viral infections, today announced that it presented data from its program for Hepatitis B virus, EBT-107, at the 2024 International HBV Meeting, that took place September 11-15, 2024, in Chicago, IL.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Excision BioTherapeutics
Sign Up For FreeTo access detailed company insights
Excision BioTherapeutics, Inc., is a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases. Excision is focused on improving the lives of chronically ill patients by excising viral genomes from infected individuals. By using CRISPR in unique ways, the Company has already demonstrated the first functional... Read More
